The Manufacturers Life Insurance Company Purchases 4,533 Shares of iShares Biotechnology ETF $IBB

The Manufacturers Life Insurance Company lifted its position in iShares Biotechnology ETF (NASDAQ:IBB) by 7.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,078 shares of the financial services provider’s stock after acquiring an additional 4,533 shares during the quarter. The Manufacturers Life Insurance Company owned 0.13% of iShares Biotechnology ETF worth $10,482,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Citigroup Inc. increased its position in iShares Biotechnology ETF by 40.9% during the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after purchasing an additional 1,521,992 shares during the period. Morgan Stanley lifted its position in shares of iShares Biotechnology ETF by 2.5% in the 4th quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after purchasing an additional 76,978 shares during the period. BNP Paribas Financial Markets lifted its position in shares of iShares Biotechnology ETF by 11.4% in the 4th quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock worth $360,064,000 after purchasing an additional 218,066 shares during the period. Raymond James Financial Inc. lifted its position in shares of iShares Biotechnology ETF by 286.2% in the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after purchasing an additional 736,881 shares during the period. Finally, LPL Financial LLC boosted its stake in shares of iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after purchasing an additional 589,033 shares in the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

Shares of IBB stock opened at $185.91 on Tuesday. The company’s 50 day moving average is $182.06 and its 200 day moving average is $174.76. iShares Biotechnology ETF has a 52-week low of $130.25 and a 52-week high of $199.05.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were given a dividend of $0.0238 per share. This represents a $0.10 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend was Monday, June 15th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.